← RIGEL PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($69.2m) | ($78.0m) | ($70.5m) | ($66.9m) | ($29.7m) | ($17.9m) | ($58.6m) | ($25.1m) | $17.5m | $367.0m | — | |
| Depreciation, Depletion and Amortization | $941k | $465k | $594k | $683k | $706k | $1.2m | $998k | $1.2m | $2.2m | $2.4m | $2.6m | |
| Amortization of Intangible Assets | — | — | — | — | — | — | $100k | $1.1m | $2.1m | $2.4m | — | |
| Deferred Income Tax Expense (Benefit) | — | — | — | — | — | — | — | $0 | $0 | ($245.9m) | ($243.3m) | |
| Share-based Payment Arrangement, Noncash Expense | $7.3m | $6.0m | $7.7m | $9.1m | $7.3m | $9.5m | $12.4m | $8.8m | $12.4m | $12.7m | $16.4m | |
| Share-based Payment Arrangement, Expense | $7.8m | $6.0m | $7.7m | $9.1m | $7.3m | $9.5m | $12.4m | $8.8m | $12.4m | $12.7m | $16.4m | |
| Restructuring Costs and Asset Impairment Charges | $319k | $319k | — | — | — | $100k | — | — | — | — | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | ($203k) | — | $4.1m | $6.0m | $5.9m | ($501k) | $24.8m | ($9.8m) | $11.1m | $10.1m | ($16.1m) | |
| Increase (Decrease) in Inventories | — | — | $839k | $366k | $126k | $4.9m | $2.4m | ($1.2m) | ($764k) | $5.6m | ($2.5m) | |
| Increase (Decrease) in Accounts Payable | $2.8m | ($2.9m) | $3.8m | ($2.2m) | ($331k) | $41k | $3.8m | ($366k) | ($3.8m) | $3.9m | ($3.3m) | |
| Net Cash Provided by (Used in) Operating Activities | ($75.9m) |
($77.6m)
-2.20%
|
($58.8m)
+24.15%
|
($41.5m)
+29.44%
|
($52.2m)
-25.72%
|
$5.9m
+111.26%
|
($73.8m)
-1354.81%
|
($5.7m)
+92.21%
|
$31.5m
+647.99%
|
$75.7m
+140.40%
|
$79.4m
+4.94%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $804k | $164k | $1.1m | $1.5m | $1.3m | $627k | $450k | $0 | $36k | $0 | ($38k) | |
| Cash, Cash Equivalents, and Short-term Investments | $74.8m | $115.8m | $128.5m | $98.1m | $57.3m | $125.0m | $58.2m | $56.9m | $77.3m | $155.0m | — | |
| Net Cash Provided by (Used in) Investing Activities | $24.9m | ($19.5m) | $25.0m | ($23.7m) | $47.5m | ($80.0m) | $72.8m | ($4.3m) | $4.1m | ($92.4m) | ($49.1m) | |
| Cash flows from financing activities: | ||||||||||||
| Proceeds from Issuance of Common Stock | $23.6m | $114.2m | $67.2m | $1.6m | $2.6m | $4.8m | $2.1m | $1.0m | $2.0m | $8.1m | — | |
| Net Cash Provided by (Used in) Financing Activities | $25.2m |
$117.7m
+367.31%
|
$71.9m
-38.91%
|
$11.4m
-84.19%
|
$12.6m
+10.61%
|
$62.7m
+398.57%
|
$6.5m
-89.55%
|
$18.4m
+180.41%
|
($11.6m)
-163.38%
|
$601k
+105.16%
|
($22.9m)
-3913.81%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | $20.7m | $38.0m | ($53.8m) | $7.9m | $18.9m | $24.5m | $32.8m | $56.7m | $40.6m | $60.9m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | — | $137k | $1.2m | $1.5m | $2.5m | $5.8m | $7.0m | $6.6m | — | |
| Income Taxes Paid, Net | — | — | — | — | — | — | — | $81k | $331k | $1.1m | — | |
| Additional Financial Items | ||||||||||||
| Accretion Expense | — | — | — | — | — | $2.8m | $700k | $700k | — | — | — | |
| Gain (Loss) on Disposition of Assets | $88k | $732k | — | — | — | — | ($138k) | ($266k) | $79k | $0 | — | |
| General and Administrative Expense | $20.9m | $37.8m | — | — | — | — | — | — | — | — | — | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | — | — | $605k | — | $0 | $881k | ($245.2m) | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | — | $7.3m | — | |
| Investment Income, Interest | $437k | $892k | $2.2m | $2.5m | $582k | $47k | $684k | $2.3m | $2.1m | $3.7m | — |